Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, an
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsAlternative strategies for proof-of-principle studies of antibacterial agentsCoagulase-negative staphylococci.Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression.In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureusTelavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensVancomycin resistance in staphylococci.In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococciRandomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.In vitro activity of PNU-100766 (linezolid), a new oxazolidinone antimicrobial, against Nocardia brasiliensis.In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic modelBactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?Clinical update on linezolid in the treatment of Gram-positive bacterial infections.Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatmentApplicability of a Single Time Point Strategy for the Prediction of Area Under the Concentration Curve of Linezolid in Patients: Superiority of Ctrough- over Cmax-Derived Linear Regression ModelsLinezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.Linezolid compared with vancomycin for the prevention of methicillin-resistant Staphylococcus aureus or Staphylococcus epidermidis vascular graft infection in rats: A randomized, controlled, experimental study.In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus.Local release of antibiotics for surgical site infection management using high-purity calcium sulfate: an in vitro elution studyIn vitro bactericidal activity of iclaprim in human plasma.Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.Effect of linezolid in comparison with that of vancomycin on glycocalix production: in vitro study.
P2860
Q24646677-CB3C8D5F-DF13-4D3B-94D9-6B0D6292C268Q26850895-DEC05347-1269-4E17-B093-FDD3FCB28E24Q30401758-8BC27CC7-0190-4087-9CCF-D0AA1E114213Q33197091-446E1836-68AE-4D93-82AD-A03B1923365DQ33556476-A2CD6957-A185-4C81-BE61-7B5192DD24BAQ33788308-4E3A64A0-F3DC-4F59-ADE6-86E44467AD59Q33906522-2E8353A1-656A-4E9F-A935-FE8777A4F1E1Q33977497-469946A4-E71B-4949-8150-179A7E7A6D43Q33981016-A7A3DE48-05BA-4251-AAA6-096B34AF096AQ33982746-BEA2029D-599F-4DB3-8D5E-CA9B69A6E1BDQ33983749-4AF143DE-49A2-4F5E-A524-865AF8299A82Q34111132-6D749E44-B18D-4A6A-98CB-A377A5E5FCA7Q34230034-FB577A92-5A4B-49D2-9659-FE669D006336Q34252432-F097B8A6-CD7F-4E54-A4D8-A40FE3AF5CE2Q34510414-AF2058CE-AA96-41C4-8CB4-F71308ECB044Q35736907-8B5999B3-9426-4D82-8EDA-CAC6BE84FFA6Q36083208-225EBBBC-CCAB-49F3-8287-7874753AAFA8Q36170841-F85C2A49-520F-4B71-9D3F-2FC3EC76A1D7Q36620071-B3B3B07B-6969-48F5-BA58-F1FD2FAE4459Q37115701-42B5D0BE-ECC2-41EB-A7A8-BFDFF4F5F01CQ37663491-104877FD-9E78-430E-8321-BA26ADB4EA76Q39730651-A712392A-0F07-4442-9263-566AAAEED249Q41762519-3B2BCD73-125D-4A8F-837C-BA639A601F2AQ42009215-57E89308-F29F-4D44-AD94-604D9063B902Q42037140-AB3809FE-892E-48C2-8A4F-FAB0996C6DA2Q42781205-5B7029B2-9422-4F91-B7CE-053CAF6EC0AF
P2860
Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, an
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Comparative in vitro activitie ...... cci, Enterococcus faecalis, an
@ast
Comparative in vitro activitie ...... cci, Enterococcus faecalis, an
@en
type
label
Comparative in vitro activitie ...... cci, Enterococcus faecalis, an
@ast
Comparative in vitro activitie ...... cci, Enterococcus faecalis, an
@en
prefLabel
Comparative in vitro activitie ...... cci, Enterococcus faecalis, an
@ast
Comparative in vitro activitie ...... cci, Enterococcus faecalis, an
@en
P2093
P2860
P1476
Comparative in vitro activitie ...... cci, Enterococcus faecalis, an
@en
P2093
D M Cappelletty
J R Aeschlimann
T Moldovan
P2860
P304
P407
P577
1998-03-01T00:00:00Z